Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

Hamilton, Ronald L.

doi:10.1111/j.1750-3639.2000.tb00269.x

Cited by 754Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and Treatments

Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

Open access

Hamilton, Ronald L.·2000·Brain Pathology

DOI 10.1111/j.1750-3639.2000.tb00269.xPMC PMC8098522

Open this paper in CoChat — free account

Abstract

Antibodies to α‐synuclein (AS) now provide a sensitive and specific method for the detection of Lewy bodies (LBs) and their use will allow a more accurate determination of the prevalence of LBs in Alzheimer's Disease (AD). Studies using AS immunohistochemistry (IHC) have found LBs in the amygdala of over 60% early onset familial AD and in 50% of Down's syndrome patients with AD, however, no studies have reported the use of AS IHC to detect LBs in a large cohort of sporadic AD. This study examined 145 sporadic AD cases diagnosed using CERAD criteria from 1995–1999 for the presence of LBs using AS IHC. AS IHC detected LBs in 88/145 (60.7%) of sporadic AD cases. Similarly, LBs were found in 56.8% of the 95 cases fulfilling the more stringent NIA‐RI criteria for the diagnosis of AD (Braak stage 5–6). In all cases with LBs, the amygdala was involved and LBs were always most numerous in this area, however, in some cases LBs in the substantia nigra were rare or not present. In conclusion, this study found that AS IHC detects LBs in the majority of sporadic AD cases and that the amygdala is the most commonly affected region.

Integrity signals

Registry

Crossref · 10.1111/j.1750-3639.2000.tb00269.x

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · see citing works
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
(1998) · Europe PMC (PubMed Central) · Cited by 1,594 · see citing works
Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542 · see citing works
The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068 · see citing works
Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981 · see citing works
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Hughes, A. J., Daniel, S. E., Blankson, S., & Lees, A. J. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540020018011 · Cited by 945 · see citing works
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.
(1997) · PubMed · Cited by 745 · see citing works
Identification of normal and pathological aging in prospectively studied nondemented elderly humans
Dickson, D. W., Crystal, H. A., Mattiace, L. A., Masur, D. M., Blau, A. D., Davies, P., Yen, S.-H., & Aronson, M. K. (1992) · Neurobiology of Aging · doi:10.1016/0197-4580(92)90027-u · Cited by 643 · see citing works
Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes
Lippa, C. F., Fujiwara, H., Mann, D. M. A., Giasson, B., Baba, M., Schmidt, M. L., Nee, L. E., O'Connell, B., Pollen, D. A., St. George-Hyslop, P., et al. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65722-7 · Cited by 533 · see citing works
Clinical-Neuropathological Correlations in Alzheimer's Disease and Related Dementias
Galasko, D., Hansen, L. A., Katzman, R., Wiederholt, W. C., Masliah, E., Terry, R. D., Hill, L. R., Lessin, P. J., & Thal, L. J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540210060013 · Cited by 407 · see citing works
Pattern of brain destruction in Parkinson's and Alzheimer's diseases
Braak, H., Braak, E., Yilmazer‐Hanke, D., de Vos, R. A. I., Jansen, E. N. H., & Böhl, J. (1996) · Journal of Neural Transmission · doi:10.1007/bf01276421 · Cited by 329 · see citing works
Cognitive decline is faster in Lewy body variant than in Alzheimer's disease
Olichney, J., Galasko, D. R., Salmon, D. P., Hofstetter, C. R., Hansen, L. A., Katzman, R., & Thal, L. J. (1998) · Neurology · doi:10.1212/wnl.51.2.351 · Cited by 305 · see citing works
Plaque-Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa
Hansen, L. A., Masliah, E., Galasko, D., & Terry, R. D. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199311000-00012 · Cited by 227 · see citing works
The Lewy-Body Variant of Alzheimer's Disease
Förstl, H., Burns, A. S., Luthert, P. J., Cairns, N. J., & Levy, R. (1993) · The British Journal of Psychiatry · doi:10.1192/bjp.162.3.385 · Cited by 221 · see citing works
Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques
Dickson, D. W., Crystal, H., Mattiace, L. A., Kress, Y., Schwagerl, A. L., Ksiȩżak-Reding, H., Davies, P., & Yen, S. H. (1989) · Acta Neuropathologica · doi:10.1007/bf00691284 · Cited by 203 · see citing works
Dementia with Lewy bodies
Mega, M. S., Masterman, D. L., Benson, D. F., Vinters, H. V., Tomiyasu, U., Craig, A. H., Foti, D. J., Kaufer, D., Scharre, D. W., Fairbanks, L. A., et al. (1996) · Neurology · doi:10.1212/wnl.47.6.1403 · Cited by 203 · see citing works
Clinical and quantitative pathologic correlates of dementia with Lewy bodies
Gómez‐Tortosa, E., Newell, K. L., Irizarry, M. C., Albert, M., Growdon, J. H., & Hyman, B. T. (1999) · Neurology · doi:10.1212/wnl.53.6.1284 · Cited by 202 · see citing works
Multicenter clinicopathological correlation in dementia
Victoroff, J., Mack, W. J., Lyness, S. A., & Chui, H. C. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1476 · Cited by 185 · see citing works
Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry.
Lennox, G. G., Lowe, J. S., Landon, M., Byrne, E. J., Mayer, R. J., & Godwin-Austen, R. B. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.11.1236 · Cited by 184 · see citing works
An evaluation of the predictive validity and inter‐rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type
McKeith, I. G., FAIRBAIRN, A. F., Bothwell, R. A., Moore, P. B., Ferrier, I. N., Thompson, P., & Perry, R. H. (1994) · Neurology · doi:10.1212/wnl.44.5.872 · Cited by 174 · see citing works
Criteria for Alzheimer's Disease and the Nosology of Dementia with Lewy Bodies
Hansen, L. A., & Samuel, W. (1997) · Neurology · doi:10.1212/wnl.48.1.126 · Cited by 149 · see citing works
Dementia with Lewy Bodies. A Distinct Non‐Alzheimer Dementia Syndrome?
Ince, P., Perry, E. K., & Morris, C. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00156.x · Cited by 123 · see citing works
Comparison of Lewy body variant of Alzheimer’s disease with pure Alzheimer’s disease
Heyman, A., Fillenbaum, G. G., Gearing, M., Mirra, S. S., Welsh-Bohmer, K. A., Peterson, B. L., & Pieper, C. F. (1999) · Neurology · doi:10.1212/wnl.52.9.1839 · Cited by 109 · see citing works
Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein
Jakes, R., Crowther, R. A., Lee, V. M. ‐., Trojanowski, J. Q., Iwatsubo, T., & Goedert, M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00411-5 · Cited by 103 · see citing works
Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients
Ince, P. G., Irving, D., MacArthur, F., & Perry, R. H. (1991) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(91)90251-2 · Cited by 87 · see citing works
Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease
Rezaie, P., Cairns, N. J., Chadwick, A. J., & Lantos, P. L. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12775-0 · Cited by 80 · see citing works
Neuropathological Diagnoses in Elderly Patients in Oslo: Alzheimers Disease, Lewy Body Disease, Vascular Lesions
Ince, P. G., McArthur, F. K., Bjertness, E., TORVIK, A., Candy, J. M., & Edwardson, J. A. (1995) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106940 · Cited by 78 · see citing works
Cerebral type of Lewy body disease
Kosaka, K., Iseki, E., Odawara, T., & Yamamoto, T. (1996) · Neuropathology · doi:10.1111/j.1440-1789.1996.tb00152.x · Cited by 61 · see citing works
Cortical Lewy bodies in Alzheimer's disease.
Kazee, A. M., & Han, L. Y. (1995) · PubMed · Cited by 38 · see citing works
The frequency of Lewy bodies in a consecutive autopsy series.
Cf, L., & Hb, H. (1998) · PubMed · Cited by 29 · see citing works
Neocortical changes in Parkinson's disease, revisited.
Sugiyama, H., Hainfellner, J. A., Yoshimura, M., et al. (1994) · PubMed · Cited by 21 · see citing works
Lewy body variant
Dickson, D. W. (1990) · Neurology · doi:10.1212/wnl.40.7.1147 · Cited by 14 · see citing works
Untitled work
Price (1999) · doi:10.1002/1531-8249(199903)45:3

Flagged first, then by citations

Research works printed but not linked: 2

[25]25. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45: 353–357. [DOI] [PubMed] [Google Scholar]
[26]26. Lopez O, Hamilton R, Becker J, Wisniewski S, Kaufer D, DeKosky S (1998) Clinical features and predictors of progression in patients with Alzheimer's disease and with the Lewy body variant of Alzheimer's disease (abstract). Neurology 50 (suppl 4): A182. [Google Scholar]

Sorted by citations

Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,105 · see citing works
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · see citing works
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345 · see citing works
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · see citing works
“LBs are frequent in the setting of moderate-to-severe levels of AD neuropathologic change [27, 59], including some early-onset familial AD cases [32, 33].”
The function of α-synuclein
Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013) · Neuron · doi:10.1016/j.neuron.2013.09.004 · Cited by 825 · see citing works
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · see citing works
The genetic epidemiology of neurodegenerative disease
Bertram, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24761 · Cited by 680 · see citing works
Protein transmission in neurodegenerative disease
Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0333-7 · Cited by 625 · see citing works
Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered
Braak, H., Bohl, J. R., Müller, C. M., Rüb, U., de Vos, R. A. I., & Del Tredici, K. (2006) · Movement Disorders · doi:10.1002/mds.21065 · Cited by 630 · see citing works
Neuropathology of Parkinson disease
Dickson, D. W. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.033 · Cited by 623 · see citing works
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211412398 · Cited by 607 · see citing works
Synergistic Interactions between Aβ, Tau, and α-Synuclein: Acceleration of Neuropathology and Cognitive Decline
Clinton, L. K., Blurton-Jones, M., Myczek, K., Trojanowski, J. Q., & LaFerla, F. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0490-10.2010 · Cited by 576 · see citing works
The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features
Ossenkoppele, R., Pijnenburg, Y. A. L., Perry, D. C., Cohn-Sheehy, B. I., Scheltens, N. M. E., Vogel, J. W., Kramer, J. H., van der Vlies, A. E., Joie, R. L., Rosen, H. J., et al. (2015) · Brain · doi:10.1093/brain/awv191 · Cited by 548 · see citing works
Current state of Alzheimer’s fluid biomarkers
Molinuevo, J. L., Ayton, S., Batrla, R., Bednar, M. M., Bittner, T., Cummings, J., Fagan, A. M., Hampel, H., Mielke, M. M., Mikulskis, A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1932-x · Cited by 518 · see citing works
α-synuclein in the pathophysiology of Alzheimer’s disease
Twohig, D., & Nielsen, H. M. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0320-x · Cited by 374 · see citing works
Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation
Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368 · see citing works
α-Synucleinopathy phenotypes
McCann, H., Stevens, C. H., Cartwright, H., & Halliday, G. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70017-8 · Cited by 364 · see citing works
Immune Signaling in Neurodegeneration
Hammond, T. R., Marsh, S. E., & Stevens, B. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.016 · Cited by 336 · see citing works
The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases
Rey, N. L., Wesson, D. W., & Brundin, P. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.013 · Cited by 257 · see citing works
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242 · see citing works
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's <i>continuum</i>
Milà‐Alomà, M., Salvadó, G., Gispert, J. D., Vilor‐Tejedor, N., Grau‐Rivera, O., Sala‐Vila, A., Sánchez‐Benavides, G., Arenaza‐Urquijo, E. M., Crous‐Bou, M., González‐de‐Echávarri, J. M., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12131 · Cited by 241 · see citing works
Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
Ping, L., Duong, D. M., Yin, L., Gearing, M., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2018) · Scientific Data · doi:10.1038/sdata.2018.36 · Cited by 221 · see citing works
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky, J., Pichlerova, K., & Hanes, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179207 · Cited by 220 · see citing works
Lewy Body Pathology in Normal Elderly Subjects
Markesbery, W. R., Jicha, G. A., Liu, H., & Schmitt, F. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ac10a7 · Cited by 210 · see citing works
Altered Proteins in the Aging Brain
Elobeid, A., Libard, S., Leino, M., Popova, S. N., & Alafuzoff, I. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw002 · Cited by 202 · see citing works
MicroRNA-153 Physiologically Inhibits Expression of Amyloid-β Precursor Protein in Cultured Human Fetal Brain Cells and Is Dysregulated in a Subset of Alzheimer Disease Patients
Long, J. M., Ray, B., & Lahiri, D. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366336 · Cited by 198 · see citing works
Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample
Brenowitz, W. D., Hubbard, R. A., Keene, C. D., Hawes, S. E., Longstreth, W. T., Woltjer, R. L., & Kukull, W. A. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.015 · Cited by 188 · see citing works
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works
Selective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis
Roussarie, J.-P., Yao, V., Rodriguez-Rodriguez, P., Oughtred, R., Rust, J., Plautz, Z., Kasturia, S., Albornoz, C., Wang, W., Schmidt, E. F., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.010 · Cited by 180 · see citing works
Lewy Body Pathology in Alzheimer's Disease
Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177 · see citing works
Correlating familial Alzheimer’s disease gene mutations with clinical phenotype
Ryan, N. S., & Rossor, M. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.92 · Cited by 176 · see citing works
Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease
Guerrero-Muñoz, M. J., Gerson, J., & Castillo-Carranza, D. L. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00464 · Cited by 168 · see citing works
Microglial TYROBP/DAP12 in Alzheimer's Disease: Transduction of Physiological and Pathological Signals Across TREM2
Haure-Mirande, J.-V., Audrain, M., Ehrlich, M. E., & Gandy, S. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00552-w · Cited by 159 · see citing works
Lewy Body Pathology in Familial Alzheimer Disease: Evidence for Disease- and Mutation-Specific Pathologic Phenotype
Leverenz, J. B., Fishel, M. A., Peskind, E. R., Montine, T. J., Nochlin, D., Steinbart, E., Raskind, M. A., Schellenberg, G. D., Bird, T. D., & Tsuang, D. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.370 · Cited by 139 · see citing works
Enteric alpha‐synuclein expression is increased in <scp>P</scp>arkinson's disease but not <scp>A</scp>lzheimer's disease
Gold, A., Turkalp, Z. T., & Munoz, D. G. (2013) · Movement Disorders · doi:10.1002/mds.25298 · Cited by 132 · see citing works
RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128 · see citing works
Retracted
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95 · see citing works
Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples
Brenowitz, W. D., Keene, C. D., Hawes, S. E., Hubbard, R. A., Longstreth, W. T., Woltjer, R. L., Crane, P. K., Larson, E. B., & Kukull, W. A. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.017 · Cited by 88 · see citing works
α-Synuclein Oligomers Induce a Unique Toxic Tau Strain
Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Gerson, J. E., & Kayed, R. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.12.018 · Cited by 84 · see citing works
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
Permanne, B., Sand, A., Ousson, S., Nény, M., Hantson, J., Schubert, R., Wiessner, C., Quattropani, A., & Beher, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00057 · Cited by 82 · see citing works
Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration
Irwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67 · see citing works
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68 · see citing works
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64 · see citing works
Network dysfunction in<i>α</i>‐synuclein transgenic mice and human Lewy body dementia
Morris, M., Sanchez, P. E., Verret, L., Beagle, A. J., Guo, W., Dubal, D., Ranasinghe, K. G., Koyama, A., Ho, K., Yu, G., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.257 · Cited by 61 · see citing works
Neuropathological correlates of volumetric MRI in autopsy-confirmed Lewy body dementia
Burton, E. J., Mukaetova-Ladinska, E. B., Perry, R. H., Jaros, E., Barber, R., & O'Brien, J. T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.015 · Cited by 43 · see citing works
Cerebrospinal fluid α‐synuclein contributes to the differential diagnosis of Alzheimer's disease
Shi, M., Tang, L., Toledo, J. B., Ginghina, C., Wang, H., Aro, P., Jensen, P. H., Weintraub, D., Chen‐Plotkin, A. S., Irwin, D. J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.015 · Cited by 42 · see citing works
Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes
Bouwmans, A. E. P., Vlaar, A. M. M., Srulijes, K., Mess, W. H., & Weber, W. E. J. (2010) · International review of neurobiology · doi:10.1016/s0074-7742(10)90009-3 · Cited by 40 · see citing works
Evaluation of Selection Bias in an Incident-Based Dementia Autopsy Case Series
Tsuang, D., Simpson, K. L., Li, G., Barnhart, R. L., Edland, S. D., Bowen, J., McCormick, W., Teri, L., Nochlin, D., Larson, E. B., et al. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000165507.67993.47 · Cited by 37 · see citing works
A new direction for Alzheimer's research
Weinstein, J. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.226381 · Cited by 20 · see citing works

Iron, the substantia nigra and related neurological disorders
Snyder, A. M., & Connor, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.005 · Cited by 137 · see citing works
Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rat
Delacruz, C., Revilla, E., Venero, J. L., Ayala, A., Cano, J., & MacHado, A. (1996) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(95)02025-x · Cited by 72 · see citing works
The morphological research on the developing rat substantia nigra
Jianzhi, Z., Ding, Y., Liu, H., et al. (2005) · Acta Academiae Medicinae Xuzhou
Changes of dopaminergic neurons in substantia nigra compact of the aged rats
Yu, S. (2009) · Journal of Clinical Neurology
No evidence for new dopaminergic neurons in the adult mammalian substantia nigra
Frielingsdorf, H., Schwarz, K., Brundin, P., & Mohapel, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401229101 · Cited by 251 · see citing works

Authors: Hamilton, R. L.
Affiliations: University of Pittsburgh (US)
Corresponding author: Hamilton, Ronald L.
ORCID: Hamilton, Ronald L.
Venue: Brain Pathology
Publisher: Wiley
Published: 2000-07
Volume: 10
Issue: 3
Pages: 378-384
ISSN: 1015-6305 (ISSN-L)
1750-3639
DOI: 10.1111/j.1750-3639.2000.tb00269.x
PMC: PMC8098522
OpenAlex: W2015020748
Cited by: 754
References: 36
Citations by year: 2026: 24 · 2025: 46 · 2024: 32 · 2023: 37 · 2022: 38 · 2021: 48 · 2020: 80 · 2019: 40 · 2018: 35 · 2017: 27 · 2016: 32 · 2015: 21 · 2014: 22 · 2013: 25 · 2012: 14
FWCI: 11.43
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2104 d)
Locations: Brain Pathology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute on Aging (AG 05-133, P50AG005133)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords: Lewy bodies, Alzheimer's disease, alpha-synuclein, immunohistochemistry, sporadic Alzheimer's disease, amygdala, substantia nigra, Braak staging
MeSH terms: Alzheimer Disease, Amygdala, Brain, Humans, Immunohistochemistry, Nerve Tissue Proteins, Lewy Bodies, Synucleins, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

Abstract

Integrity signals

Claims the paper makes

Self-check

Cites

Cited by

Related

Record

About these checks